Table 1 Baseline characteristics by DGF recovery status.

Recipient age at KT

46.89 ± 10.70

46.86 ± 10.58

48.77 ± 10.33

0.617

Male recipient (%)

165 (58.7%)

38 (54.3%)

19 (55.9%)

0.847

Diabetes as the cause of ESRD

31 (11.0%)

10 (14.3%)

5 (14.7%)

0.659

Number of HLA mismatches

2.75 ± 1.55

3.11 ± 1.26

3.01 ± 1.52

0.121

Recipient BMI (kg/m²)

22.29 ± 3.41

22.76 ± 3.33

22.19 ± 2.58

0.545

Pretransplant dialysis duration (m)

81.31 ± 47.45

93.79 ± 45.63

86.21 ± 47.12

0.136

Re-transplantation

43 (15.3%)

12 (17.1%)

7 (20.6%)

0.706

Donor age at KT

44.02 ± 13.85

45.66 ± 11.11

49.68 ± 11.68

0.053

Male donor (%)

181 (64.4%)

44 (62.9%)

21 (61.8%)

0.936

Donor BMI (kg/m²)

23.08 ± 3.68

22.86 ± 3.37

24.37 ± 4.47

0.122

Mean final serum Cr (mg/dL)

1.21 ± 0.75

1.97 ± 1.41

1.96 ± 1.24

 < 0.001*

Donor history of HTN (%)

61 (21.7%)

17 (24.3%)

11 (32.4%)

0.368

Donor history of DM (%)

19 (6.8%)

2 (2.9%)

4 (11.8%)

0.736

Expanded criteria donor (%)

70 (24.9%)

24 (34.3%)

14 (41.2%)

0.060

Cold ischemic time

0.128

    <4 hours

90 (32.3%)

22 (31.4%)

9 (25.7%)

    4–8 hours

160 (57.3%)

36 (51.4%)

20 (57.1%)

    8–12 hours

20 (7.2%)

10 (14.3%)

3 (8.6%)

    >12 hours

9 (3.2%)

2 (2.9%)

3 (8.6%)

Induction therapy (%)

<0.001*

    ATG

22 (11.7%)

31 (44.3%)

19 (55.9%)

    Basiliximab

259 (92.2%)

39 (55.7%)

15 (44.1%)

CNI at discharge (%)

0.419

    Tacrolimus

223 (79.4%)

51 (72.9%)

28 (82.4%)

   Cyclosporine

58 (20.6%)

19 (27.1%)

6 (17.6%)

PRA (%)

0.128

    0%

153 (54.4%)

37 (52.9%)

12 (35.3%)

    1 – 20%

44 (15.7%)

6 (8.6%)

6 (17.6%)

    21 – 80%

55 (19.6%)

18 (25.7%)

13 (38.2%)

    >80%

29 (10.3%)

9 (12.9%)

3 (8.8%)